Aberdeen Group plc Has $257.62 Million Stake in Boston Scientific Corporation $BSX

Aberdeen Group plc raised its stake in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,644,944 shares of the medical equipment provider’s stock after purchasing an additional 52,490 shares during the period. Aberdeen Group plc owned 0.18% of Boston Scientific worth $257,618,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BSX. Vanguard Group Inc. increased its position in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the period. State Street Corp grew its stake in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC increased its position in Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank acquired a new stake in Boston Scientific in the 2nd quarter worth about $2,089,937,000. Finally, Invesco Ltd. boosted its holdings in Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after purchasing an additional 226,578 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.8%

NYSE BSX opened at $74.72 on Friday. The firm has a market capitalization of $110.76 billion, a PE ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The business’s 50-day moving average price is $90.93 and its two-hundred day moving average price is $97.63. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12 month low of $72.69 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BSX shares. Evercore dropped their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Canaccord Genuity Group decreased their price target on Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Citigroup cut their price objective on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Royal Bank Of Canada decreased their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Needham & Company LLC dropped their target price on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $109.43.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.